SMT201300034B - Genetica inversa che utilizza promotori pol i non-endogeni - Google Patents

Genetica inversa che utilizza promotori pol i non-endogeni

Info

Publication number
SMT201300034B
SMT201300034B SM201300034T SM201300034T SMT201300034B SM T201300034 B SMT201300034 B SM T201300034B SM 201300034 T SM201300034 T SM 201300034T SM 201300034 T SM201300034 T SM 201300034T SM T201300034 B SMT201300034 B SM T201300034B
Authority
SM
San Marino
Prior art keywords
polis
promoters
endogenous
reverse genetics
genetics
Prior art date
Application number
SM201300034T
Other languages
English (en)
Inventor
Philip Dormitzer
Pirada Suphaphiphat
Bjoern Keiner
Michael Franti
Peter Mason
Stephania Crotta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201300034B publication Critical patent/SMT201300034B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16041Use of virus, viral particle or viral elements as a vector
    • C12N2760/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16051Methods of production or purification of viral material
    • C12N2760/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mushroom Cultivation (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
SM201300034T 2009-05-21 2013-03-27 Genetica inversa che utilizza promotori pol i non-endogeni SMT201300034B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21691909P 2009-05-21 2009-05-21
PCT/IB2010/001332 WO2010133964A1 (en) 2009-05-21 2010-05-21 Reverse genetics using non-endogenous pol i promoters

Publications (1)

Publication Number Publication Date
SMT201300034B true SMT201300034B (it) 2013-05-06

Family

ID=42338045

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300034T SMT201300034B (it) 2009-05-21 2013-03-27 Genetica inversa che utilizza promotori pol i non-endogeni

Country Status (19)

Country Link
US (3) US9072702B2 (it)
EP (2) EP2401384B1 (it)
JP (2) JP5836266B2 (it)
KR (1) KR101800245B1 (it)
CN (1) CN102597246B (it)
AU (1) AU2010250832B2 (it)
BR (1) BRPI1011171A2 (it)
CA (1) CA2762802A1 (it)
DK (1) DK2401384T3 (it)
EA (1) EA021009B1 (it)
ES (1) ES2394797T3 (it)
HK (1) HK1165827A1 (it)
HR (1) HRP20121048T1 (it)
NZ (1) NZ596432A (it)
PL (1) PL2401384T3 (it)
PT (1) PT2401384E (it)
SI (1) SI2401384T1 (it)
SM (1) SMT201300034B (it)
WO (1) WO2010133964A1 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
SI2401384T1 (sl) * 2009-05-21 2013-01-31 Novartis Ag Reverzna genetika z uporabo neendogenih pol i promotorjev
KR101323582B1 (ko) * 2011-03-17 2013-10-30 충북대학교 산학협력단 Vero 세포 유래의 polⅠ 프로모터 및 이를 포함하는 재조합 벡터
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
WO2016148195A1 (ja) * 2015-03-17 2016-09-22 一般財団法人阪大微生物病研究会 インフルエンザウイルス作出用細胞
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
CN115380107A (zh) 2019-11-18 2022-11-22 思齐乐私人有限公司 用于产生重配流感病毒的方法
BR102020010208A2 (pt) 2020-05-21 2022-04-12 Fundação Oswaldo Cruz Construção de ácido nucleico, virus influenza recombinante, método para preparar um virus influenza recombinante, composição, e, uso.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
KR100797547B1 (ko) 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
AR032575A1 (es) 2001-02-23 2003-11-12 Smithkline Beecham Biolog Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
CA2421086A1 (fr) * 2003-02-28 2004-08-28 Institut Pasteur Promoteur de l'arn polymerase i de poulet et son utilisation
SI1742659T1 (sl) 2004-04-05 2013-07-31 Zoetis P Llc Mikrofluidizirane emulzije olja v vodi in sestavki cepiv
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
MXPA06013411A (es) 2004-05-20 2007-07-04 Id Biomedical Corp Procedimiento para la produccion de una vacuna contra la influenza.
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2613283A1 (en) * 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US20090220541A1 (en) 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
WO2008043774A1 (en) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
SI2401384T1 (sl) * 2009-05-21 2013-01-31 Novartis Ag Reverzna genetika z uporabo neendogenih pol i promotorjev

Also Published As

Publication number Publication date
PL2401384T3 (pl) 2013-03-29
HK1165827A1 (en) 2012-10-12
NZ596432A (en) 2013-05-31
AU2010250832B2 (en) 2013-10-03
CN102597246B (zh) 2014-02-26
JP5836266B2 (ja) 2015-12-24
US20190284575A1 (en) 2019-09-19
WO2010133964A1 (en) 2010-11-25
US20160024525A1 (en) 2016-01-28
KR20120028328A (ko) 2012-03-22
US20120189656A1 (en) 2012-07-26
CA2762802A1 (en) 2010-11-25
JP2015204843A (ja) 2015-11-19
EA201171449A1 (ru) 2012-05-30
CN102597246A (zh) 2012-07-18
HRP20121048T1 (hr) 2013-02-28
EA021009B1 (ru) 2015-03-31
SI2401384T1 (sl) 2013-01-31
EP2401384A1 (en) 2012-01-04
AU2010250832A1 (en) 2011-12-08
JP2012527228A (ja) 2012-11-08
ES2394797T3 (es) 2013-02-05
KR101800245B1 (ko) 2017-11-22
BRPI1011171A2 (pt) 2015-08-25
EP2401384B1 (en) 2012-10-03
US9072702B2 (en) 2015-07-07
EP2573184A1 (en) 2013-03-27
PT2401384E (pt) 2012-12-19
DK2401384T3 (da) 2013-01-14

Similar Documents

Publication Publication Date Title
SMT201300034B (it) Genetica inversa che utilizza promotori pol i non-endogeni
NL301211I1 (nl) Olipudase alfa
FI20090273A0 (fi) Hissi
DK3591046T3 (da) Amylasepolypeptide
DK2421373T3 (da) Tarmrensningssystem
DK2510030T3 (da) Polyurethan-præpolymerer
IT1393741B1 (it) Struttura di pavimento flottante
BR112012025842A2 (pt) suporte flutuante
BRPI1013808A2 (pt) promotores regulados por luz
DK2494125T3 (da) Pudsesystem
FI20086106A (fi) Nastarenkaan nasta
DK2440709T3 (da) Flydende stabiliseringsindretning
FR2960210B1 (fr) Structure flottante munie de supports
NO20093038A (no) Skip
AT506246A3 (de) Flexibler silo
FR2969575B1 (fr) Structure flottante
BRPI0810093A2 (pt) Promotor de formação de nevrite
TH112669B (th) เทอร์โมเซท พอลิยูรีเธน
ES1071069Y (es) Refuerzo lobular
FI20095907A (fi) Sideraudoite
FI20090143A (fi) Hissin kaapelointijärjestely
FI20080555A0 (fi) Nukke
ES1069921Y (es) Guarda-objetos flotante hinchable
ES1070738Y (es) Flotador salvavidas
FIU20090462U0 (fi) Raudoitusrakenne